Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Tactile Systems Technology Inc. (TCMD) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Medical Devices
$25.25
-0.15 (-0.59%)Did TCMD Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Tactile Systems is one of their latest high-conviction picks.
Based on our analysis of 2 Wall Street analysts, TCMD has a bullish consensus with a median price target of $40.00 (ranging from $36.00 to $42.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $25.25, the median forecast implies a 58.4% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for TCMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2026 | BTIG | Ryan Zimmerman | Buy | Reiterates | $40.00 |
| May 7, 2026 | B. Riley Securities | Buy | Upgrade | $N/A | |
| May 5, 2026 | BTIG | Buy | Maintains | $N/A | |
| Feb 18, 2026 | B. Riley Securities | Neutral | Maintains | $N/A | |
| Feb 18, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 18, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jan 5, 2026 | Piper Sandler | Overweight | Upgrade | $N/A | |
| Nov 4, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Nov 4, 2025 | Piper Sandler | Neutral | Reiterates | $N/A | |
| Nov 4, 2025 | BTIG | Buy | Upgrade | $N/A | |
| Oct 3, 2025 | Lake Street | Buy | Initiates | $N/A | |
| Aug 5, 2025 | B. Riley Securities | Neutral | Maintains | $N/A | |
| May 6, 2025 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Feb 19, 2025 | B. Riley Securities | Neutral | Downgrade | $N/A | |
| Nov 5, 2024 | BTIG | Neutral | Downgrade | $N/A | |
| Sep 26, 2024 | B. Riley Securities | Buy | Initiates | $N/A | |
| Aug 8, 2023 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 9, 2023 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 9, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Apr 17, 2023 | BTIG | Buy | Maintains | $N/A |
The following stocks are similar to Tactile Systems based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tactile Systems Technology Inc. has a market capitalization of $569.55M with a P/E ratio of 29.2x. The company generates $343.52M in trailing twelve-month revenue with a 5.9% profit margin.
Revenue growth is +22.8% quarter-over-quarter, while maintaining an operating margin of -2.0% and return on equity of +9.6%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Develops medical devices for chronic disease treatment.
The company generates revenue by developing and marketing advanced pneumatic compression devices that treat chronic swelling conditions. These products are sold to healthcare providers, hospitals, and clinics, allowing Tactile Systems Technology Inc. to reach a diverse patient base in need of specialized care.
Tactile Systems Technology Inc. is based in the United States and is known for its innovative approach to healthcare delivery. The company focuses on non-invasive treatment options, which enhances patient management solutions and improves overall quality of life for patients suffering from chronic diseases.
Healthcare
Medical Devices
1,037
Ms. Sheri Louise Dodd
United States
2016
Tactile Systems Technology launched its next-gen AffloVest therapy system for chronic respiratory conditions, enhancing patient comfort and usability while maintaining indications for use.
The launch of the next-generation AffloVest enhances Tactile Medical's product offering, potentially increasing market share and revenue, which can positively impact stock performance.
Tactile Systems Technology, Inc. (Nasdaq: TCMD) will present at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, at 9:20 a.m. Central Time.
Tactile Medical's participation in a prominent investment conference signals potential growth opportunities and increased visibility, which could influence stock performance and investor sentiment.
Zacks uses its Rank system, focusing on earnings estimates and revisions, to identify strong stocks while also monitoring value, growth, and momentum trends.
The Zacks Rank system highlights stocks with favorable earnings estimates, indicating potential growth. Tracking these trends can help investors identify high-performing investment opportunities.
Tactile Systems Technology, Inc. (TCMD) held its Q1 2026 earnings call, detailing financial performance and operational updates. Further specifics were discussed during the call.
The Q1 2026 earnings call for Tactile Systems Technology provides insights into the company's financial performance, growth prospects, and market trends, influencing investment decisions and stock valuations.
Tactile Systems Technology reported Q1 2026 revenue of $75.3M, up 23% YoY, with a gross margin of 76.5%. The net loss narrowed to $1.8M, and adjusted EBITDA was $3.7M. Share repurchase of $1.1M completed.
Tactile Medicalโs 23% revenue growth and improved margins signal strong demand and operational efficiency, enhancing investor confidence. FDA clearance for new products may drive future revenues.
Tactile Systems Technology (TCMD) reported a Q3 loss of $0.08 per share, exceeding the expected loss of $0.07, but improved from a loss of $0.13 per share a year earlier.
TCMD's larger-than-expected loss signals ongoing financial struggles, potentially impacting stock performance and investor confidence. Year-over-year improvement may provide some reassurance.
Based on our analysis of 2 Wall Street analysts, Tactile Systems Technology Inc. (TCMD) has a median price target of $40.00. The highest price target is $42.00 and the lowest is $36.00.
According to current analyst ratings, TCMD has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.25. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict TCMD stock could reach $40.00 in the next 12 months. This represents a 58.4% increase from the current price of $25.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company generates revenue by developing and marketing advanced pneumatic compression devices that treat chronic swelling conditions. These products are sold to healthcare providers, hospitals, and clinics, allowing Tactile Systems Technology Inc. to reach a diverse patient base in need of specialized care.
The highest price target for TCMD is $42.00 from at , which represents a 66.3% increase from the current price of $25.25.
The lowest price target for TCMD is $36.00 from at , which represents a 42.6% increase from the current price of $25.25.
The overall analyst consensus for TCMD is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $40.00.
Stock price projections, including those for Tactile Systems Technology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.